As of March 23, 2026, Aclaris Therapeutics's top three insider holders are Braden Michael Leonard (TenPercentOwner, 14.25Mn shares), Neal Walker (Ceo, 1.54Mn shares), Anand Mehra (Director, 714.82K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Braden Michael Leonard | 0 | 14,250,000 | 05 Aug, 2024 | |
| Neal Walker | Ceo | 1,543,886 | 0 | 05 Feb, 2026 |
| Anand Mehra | 714,823 | 0 | 09 Jun, 2025 | |
| Andrew N Schiff | 0 | 434,455 | 14 Nov, 2022 | |
| Joseph Monahan | Chief Scientific Officer | 265,662 | 0 | 04 Mar, 2025 |
| Frank Ruffo | Chief Financial Officer | 201,883 | 0 | 14 Mar, 2022 |
| James Loerop | Chief Business Officer | 192,260 | 0 | 05 Feb, 2026 |
| Kevin Balthaser | Chief Financial Officer | 187,453 | 0 | 03 Mar, 2026 |
| Kamil Ali-Jackson | Chief Legal Officer | 160,214 | 0 | 05 Jan, 2022 |
| David N. Gordon | Chief Medical Officer | 147,447 | 0 | 14 Jul, 2021 |
| Christopher P. Molineaux | 57,956 | 0 | 09 Jun, 2025 | |
| Hugh M. Davis | President And Coo | 45,425 | 0 | 05 Feb, 2026 |
| Douglas J. Manion | Pres And Ceo | 41,813 | 0 | 03 Jan, 2024 |
| William D. Humphries | 33,525 | 0 | 09 Jun, 2025 | |
| Andrew Kenneth William Powell | 33,523 | 0 | 04 Jun, 2024 | |
| Bryan M. Reasons | 28,732 | 0 | 04 Jun, 2024 | |
| Maxine Gowen | 21,754 | 0 | 09 Jun, 2025 | |
| Vincent Milano | 17,316 | 0 | 09 Jun, 2025 | |
| Andrew N Schiff | 13,960 | 0 | 09 Jun, 2025 | |
| Gail Cawkwell | Chief Medical Officer | 9,593 | 0 | 05 Jul, 2023 |
| Capital Management Iii, Llc Foresite | 0 | 8,276 | 03 Nov, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 01 Mar, 2026 | Kevin Balthaser | Common Stock | A | 2,375 | - | 188,130 | D | M |
| 01 Mar, 2026 | Kevin Balthaser | Common Stock | D | 677 | $2.87 | 187,453 | D | F |
| 01 Mar, 2026 | Kevin Balthaser | Restricted Stock Units | D | 2,375 | $0.00 | 0 | D | M |
| 02 Feb, 2026 | Neal Walker | Restricted Stock Units | A | 274,800 | $0.00 | 274,800 | D | A |
| 02 Feb, 2026 | Hugh M. Davis | Restricted Stock Units | A | 96,100 | $0.00 | 96,100 | D | A |
| 02 Feb, 2026 | James Loerop | Restricted Stock Units | A | 97,700 | $0.00 | 97,700 | D | A |
| 02 Feb, 2026 | Kevin Balthaser | Restricted Stock Units | A | 99,100 | $0.00 | 99,100 | D | A |
| 02 Feb, 2026 | Jesse Wayne Hall | Restricted Stock Units | A | 98,100 | $0.00 | 98,100 | D | A |
| 02 Feb, 2026 | Roland Wilhelm Kolbeck | Restricted Stock Units | A | 95,700 | $0.00 | 95,700 | D | A |
| 02 Feb, 2026 | Roland Wilhelm Kolbeck | Employee Stock Option (Right to Buy) | A | 334,900 | $0.00 | 334,900 | D | A |
| 02 Feb, 2026 | James Loerop | Employee Stock Option (Right to Buy) | A | 341,900 | $0.00 | 341,900 | D | A |
| 02 Feb, 2026 | Neal Walker | Employee Stock Option (Right to Buy) | A | 961,700 | $0.00 | 961,700 | D | A |
| 02 Feb, 2026 | Kevin Balthaser | Employee Stock Option (Right to Buy) | A | 346,800 | $0.00 | 346,800 | D | A |
| 02 Feb, 2026 | Hugh M. Davis | Employee Stock Option (Right to Buy) | A | 336,300 | $0.00 | 336,300 | D | A |
| 02 Feb, 2026 | Jesse Wayne Hall | Employee Stock Option (Right to Buy) | A | 343,300 | $0.00 | 343,300 | D | A |
| 03 Feb, 2026 | Hugh M. Davis | Common Stock | A | 18,675 | - | 45,425 | D | M |
| 01 Feb, 2026 | James Loerop | Common Stock | A | 11,250 | - | 165,758 | D | M |
| 03 Feb, 2026 | James Loerop | Common Stock | A | 20,875 | - | 198,197 | D | M |
| 03 Feb, 2026 | Kevin Balthaser | Common Stock | A | 22,025 | - | 192,204 | D | M |
| 03 Feb, 2026 | Neal Walker | Common Stock | A | 63,475 | - | 1,562,497 | D | M |